Cesaro, Simone Ljungman, Per Mikulska, Malgorzata Hirsch, Hans H von Lilienfeld-Toal, Marie Cordonnier, Catherine Meylan, Sylvain Mehra, Varun Styczynski, Jan Marchesi, Francesco
...
Published in
Leukemia
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel virus that spread worldwide from 2019 causing the Coronavirus disease 19 (COVID-19) pandemic. SARS-CoV-2 infection is characterised by an initial viral phase followed in some patients by a severe inflammatory phase. Importantly, immunocompromised patients may have a prolonged v...
Zarling, Lucas C Othus, Megan Sandmaier, Brenda M Milano, Filippo Schoch, Gary Davis, Chris Bleakley, Marie Deeg, H Joachim Appelbaum, Frederick R Storb, Rainer
...
Published in
Leukemia
There is long-standing interest in estimating non-relapse mortality (NRM) after allogeneic hematopoietic cell transplantation (HCT) for AML, but existing tools have limited discriminative capacity. Using single-institution data from 861 adults with AML, we retrospectively examined the Treatment-Related Mortality (TRM) score, originally developed to...
Récher, Christian Röllig, Christoph Bérard, Emilie Bertoli, Sarah Dumas, Pierre-Yves Tavitian, Suzanne Kramer, Michael Serve, Hubert Bornhäuser, Martin Platzbecker, Uwe
...
Published in
Leukemia
The outcome of acute myeloid leukemia patients aged 70 years or older is poor. Defining the best treatment option remains controversial especially when choosing between intensive chemotherapy and hypomethylating agents. We set up a multicentric European database collecting data of 3 700 newly diagnosed acute myeloid leukemia patients ≥70 years. The...
Spohr, Corinna Poggio, Teresa Andrieux, Geoffroy Schönberger, Katharina Cabezas-Wallscheid, Nina Boerries, Melanie Halbach, Sebastian Illert, Anna L Brummer, Tilman
Published in
Leukemia
Internal tandem duplications (ITD) of the FMS-like tyrosine kinase 3 (FLT3) predict poor prognosis in acute myeloid leukemia (AML) and often co-exist with inactivating DNMT3A mutations. In vitro studies implicated Grb2-associated binder 2 (GAB2) as FLT3-ITD effector. Utilizing a Flt3-ITD knock-in, Dnmt3a haploinsufficient mouse model, we demonstrat...
Shimomura, Yoshimitsu Sobue, Tomotaka Hirabayashi, Shigeki Kondo, Tadakazu Mizuno, Shohei Kanda, Junya Fujino, Takahiro Kataoka, Keisuke Uchida, Naoyuki Eto, Tetsuya
...
Published in
Leukemia
Cord blood transplantation (CBT) is an alternative donor transplantation method and has the advantages of rapid availability and the possibility of inducing a more potent graft-versus-leukemia effect, leading to a lower relapse rate for patients with non-remission relapse and refractory acute myeloid leukemia (R/R AML). This study aimed to investig...
Johnson, Daniel T Zhou, Jiarong Kroll, Ashley V Fang, Ronnie H Yan, Ming Xiao, Crystal Chen, Xiufen Kline, Justin Zhang, Liangfang Zhang, Dong-Er
...
Published in
Leukemia
Cancer vaccines are promising treatments to prevent relapse after chemotherapy in acute myeloid leukemia (AML) patients, particularly for those who cannot tolerate intensive consolidation therapies. Here, we report the development of an AML cell membrane-coated nanoparticle (AMCNP) vaccine platform, in which immune-stimulatory adjuvant-loaded nanop...
Assmann, Jorn L J C Leon, Leticia G Stavast, Christiaan J van den Bogaerdt, Sanne E Schilperoord-Vermeulen, Joyce Sandberg, Yorick Bellido, Mar Erkeland, Stefan J Feith, David J Loughran, Thomas P Jr
...
Published in
Leukemia
T-LGL cells arise as a consequence of chronic antigenic stimulation and inflammation and thrive because of constitutive activation of the STAT3 and ERK pathway. Notably, in 40% of patients, constitutive STAT3 activation is due to STAT3 activating mutations, whereas in 60% this is unknown. As miRNAs are amongst the most potent regulators in health a...
Sunthankar, Kathryn I Jenkins, Matthew T Cote, Candace H Patel, Sweta B Welner, Robert S Ferrell, P Brent
Published in
Leukemia
Mutations in isocitrate dehydrogenase 2 (IDH2) have been noted to impact cellular differentiation in addition to DNA and histone methylation. However, little is known about the impact of IDH2 mutations on intracellular signaling. Using an isogenic cell line model, we investigated both differentiation and signaling responses in IDH2 mutant cells and...
Bertram, Katrin Leary, Peter John Boudesco, Christophe Fullin, Jonas Stirm, Kristin Dalal, Vineet Zenz, Thorsten Tzankov, Alexandar Müller, Anne
Published in
Leukemia
Numerous targeted therapies have been developed for diffuse large B-cell lymphoma, but the results of late-stage clinical trials were mostly disappointing and have led to very few new regulatory approvals. Here, we use single and combinatorial drug response profiling to show that the combined inhibition of the anti-apoptotic protein Bcl-2 and of th...
Wilson, Elisabeth R Helton, Nichole M Heath, Sharon E Fulton, Robert S Payton, Jacqueline E Welch, John S Walter, Matthew J Westervelt, Peter DiPersio, John F Link, Daniel C
...
Published in
Leukemia
Recurrent mutations in IDH1 or IDH2 in acute myeloid leukemia (AML) are associated with increased DNA methylation, but the genome-wide patterns of this hypermethylation phenotype have not been comprehensively studied in AML samples. We analyzed whole-genome bisulfite sequencing data from 15 primary AML samples with IDH1 or IDH2 mutations, which ide...
